Search - tctmd.com

Displaying 221 - 240 of 963

Sort: Relevancy | Date

Presentation TCT 2017

Established TMVR 4: Intrepid - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Vinayak Bapat

October 31, 2017

Presentation TCT 2017

ABSORB IV 30-Day Results: Is Improved Technique Reflected in Superior Early Outcomes?

Presenter: Azeem Latib, Dean J. Kereiakes

October 31, 2017

Presentation TCT 2017

Established TMVR 3: Tendyne - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, David W.M. Muller

October 31, 2017

Presentation TCT 2017

Insights From the CABG Arms in EXCEL and NOBLE: What Met Expectations, What Didnt?

Presenter: Antonio Colombo, David E. Kandzari, John D. Puskas

October 31, 2017

Presentation TCT 2017

Featured Lecture: ABSORB Program 3-Year Meta-Analysis and Adjusted PSP Evaluation - Lessons Learned With a First Generation Scaffold

Presenter: Azeem Latib, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

Established TMVR 2: Tiara - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Anson Cheung

October 31, 2017

Presentation TCT 2017

Insights From New Meta-Analyses of PCI vs CABG for Left Main Revascularization

Presenter: Antonio Colombo, David E. Kandzari, Davide Capodanno

October 31, 2017

Presentation TCT 2017

ABSORB II at 4 Years: Clinical Outcomes Beyond the Cusp of Complete Bioresorption

Presenter: Azeem Latib, Bernard R. Chevalier

October 31, 2017

Presentation TCT 2017

Established TMVR 1: Cardiaq - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, James B. Hermiller Jr.

October 31, 2017

Presentation TCT 2017

NOBLE: Core Findings Revisited and New Data

Presenter: Antonio Colombo, David E. Kandzari, Evald H. Christiansen

October 31, 2017

Presentation TCT 2017

ABSORB in STEMI I: TROFI II 3-Year Clinical Outcomes and Correlations With the 6-Month OCT Findings

Presenter: Azeem Latib, Manel Sabate

October 31, 2017

Presentation TCT 2017

New Insights From AIDA: Subgroups and Predictors of Adverse Events

Presenter: Azeem Latib, Joanna J. Wykrzykowska

October 31, 2017

Presentation TCT 2017

TCT 571: Different Tissue Morphology of In-stent Restenosis in Hemodialysis Patient Compared With Non-hemodialysis Patients: A Prospective Multicenter Optical Coherence Tomography Registry

Presenter: Francesco Prati, Renu Virmani, Yoshinori Nagasawa, MD

October 31, 2017

Presentation TCT 2017

RIBS IV: 3-Year Outcomes From a Randomized Trial of a Metallic DES vs a Drug-Eluting Balloon in Patients With DES Restenosis

Presenter: Thomas F. Luscher, Fernando Alfonso

October 31, 2017

Presentation TCT 2017

Bioresorbable Scaffolds One Year After Approval: FDA Perspectives on Current and Future BRS

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Andrew Farb

October 31, 2017

Presentation TCT 2017

Bioresorbable Scaffolds One Year After Approval: Physician-scientist Perspectives on Current and Future BRS

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

TCT 16: Prospective, Multicenter Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold - Imaging Outcomes and Five-Year Clinical and Imaging Results

Presenter: Stephan Achenbach, Jacques J. Koolen, Stefan Verheye

October 31, 2017

Presentation TCT 2017

ILUMIEN III: 1-Year Outcomes From a Randomized Trial of OCT-Guided vs IVUS-Guided vs Angiography-Guided Stent Implantation

Presenter: Thomas F. Luscher, Ziad A. Ali

October 31, 2017

Presentation TCT 2017

FDA Perspectives on Short DAPT IDE Trials

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee

October 31, 2017

Presentation TCT 2017

TCT 13: A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease (FUTURE-I) - One-Year Clinical and Imaging Outcomes

Presenter: Stephan Achenbach, Jacques J. Koolen, Bo Xu

October 31, 2017

Advertisement

Established TMVR 4: Intrepid - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

ABSORB IV 30-Day Results: Is Improved Technique Reflected in Superior Early Outcomes?

Established TMVR 3: Tendyne - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Insights From the CABG Arms in EXCEL and NOBLE: What Met Expectations, What Didnt?

Featured Lecture: ABSORB Program 3-Year Meta-Analysis and Adjusted PSP Evaluation - Lessons Learned With a First Generation Scaffold

Established TMVR 2: Tiara - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Insights From New Meta-Analyses of PCI vs CABG for Left Main Revascularization

ABSORB II at 4 Years: Clinical Outcomes Beyond the Cusp of Complete Bioresorption

Established TMVR 1: Cardiaq - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

NOBLE: Core Findings Revisited and New Data

ABSORB in STEMI I: TROFI II 3-Year Clinical Outcomes and Correlations With the 6-Month OCT Findings

New Insights From AIDA: Subgroups and Predictors of Adverse Events

TCT 571: Different Tissue Morphology of In-stent Restenosis in Hemodialysis Patient Compared With Non-hemodialysis Patients: A Prospective Multicenter Optical Coherence Tomography Registry

RIBS IV: 3-Year Outcomes From a Randomized Trial of a Metallic DES vs a Drug-Eluting Balloon in Patients With DES Restenosis

Bioresorbable Scaffolds One Year After Approval: FDA Perspectives on Current and Future BRS

Bioresorbable Scaffolds One Year After Approval: Physician-scientist Perspectives on Current and Future BRS

TCT 16: Prospective, Multicenter Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold - Imaging Outcomes and Five-Year Clinical and Imaging Results

ILUMIEN III: 1-Year Outcomes From a Randomized Trial of OCT-Guided vs IVUS-Guided vs Angiography-Guided Stent Implantation

FDA Perspectives on Short DAPT IDE Trials

TCT 13: A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease (FUTURE-I) - One-Year Clinical and Imaging Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content